nach oben

European Archives of Oto-Rhino-Laryngology

Erschienen in:

01.10.2010 | Head and Neck

Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma

verfasst von: Takenori Ogawa, Kazumi Ogawa, Kiyoto Shiga, Toru Furukawa, Hiroki Nagase, Sho Hashimoto, Toshimitsu Kobayashi, Akira Horii

Erschienen in: European Archives of Oto-Rhino-Laryngology | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Ten head and neck squamous cell carcinoma (HNSCC) cell lines that had acquired cis-diamminedichloroplatinum (CDDP) resistance were successfully established by means of in vitro culture with CDDP. Flow cytometry analysis showed the significantly decreased induction of apoptosis after the CDDP treatment in the acquired CDDP-resistant sublines. Among these, RPMI2650CR showed a 9.38-fold increased IC50 in comparison with the parental cell line, RPMI2650. The identification of the resistance-related gene clusters was conducted between RPMI2650CR and RPMI2650 using two distinct microarray platforms. The expressional profiles were quite similar, suggesting that a limited number of genes regulate the acquisition of CDDP resistance. IGF2 was found to be one of the candidates for acquired CDDP-resistance. The introduction of IGF2 into RPMI2650 caused CDDP resistance along with suppression of CDDP-dependent apoptosis. On the other hand, siRNA-mediated knockdown of IGF2 caused reduction of acquired CDDP-resistance in RPMI2650CR. These results demonstrate that expression of IGF2 plays an important and critical role in CDDP resistance in a HNSCC cell line RPMI2650. These findings suggest the possibility for developing a new strategy for treating patients with HNSCC, particularly those with acquired CDDP resistance, by combining CDDP with inhibition of the IGF2 pathway.

Nur mit Berechtigung zugänglich

Ferlay J, Bray F, Pisani P, Parkin DM (2004) GLOBOCAN 2002: cancer incidence, mortality and prevalence worldwide. IARC Cancer Base, No5, ver. 20. IARC Press, Lyon

Forastiere AA, Goepfert H, Maor M, Pajak TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, Peters G, Lee DJ, Leaf A, Ensley J, Cooper J (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098CrossRefPubMed

Adelstein DJ, Li Y, Adams GL, Wagner H Jr, Kish JA, Ensley JF, Schuller DE, Forastiere AA (2003) An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 21:92–98CrossRefPubMed

Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M (2004) European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 350:1945–1952CrossRefPubMed

Ogawa T, Furukawa T, Shiga K, Hashimoto S, Ogawa K, Kobayashi T, Horii A (2010) A cDNA microarray analysis identifies 52 genes associated with CDDP susceptibility in head and neck squamous cell carcinoma cell lines. Eur Arch Otorhinolaryngol 267:123–129CrossRef

Higuchi EE, Oridate N, Furuta Y, Suzuki S, Hatakeyama H, Sawa H, Sunayashiki-Kusuzaki K, Yamazaki K, Inuyama Y, Fukuda S (2003) Differentially expressed genes associated with CIS-diamminedichloroplatinum (II) resistance in head and neck cancer using differential display and cDNA microarray. Head Neck 25:187–193CrossRefPubMed

Hockley SL, Mathijs K, Staal YC, Brewer D, Giddings I, van Delft JH, Phillips DH (2009) Interlaboratory and interplatform comparison of microarray gene expression analysis of HepG2 cells exposed to benzo(a)pyrene. OMICS 13:115–125CrossRefPubMed

Iwasaki I, Sugiyama H, Kanazawa S, Hemmi H (2002) Establishment of cisplatin-resistant variant of human nouroblastoma cell lines, TWG and GOTO, and their drug cross resistance profiles. Cancer Chemother Pharmacol 49:438–444CrossRefPubMed

Tounekti O, Belehradek J Jr, Mir LM (1995) Relationships between DNA fragmentation, chromatin condensation, and changes in flow cytometry profiles detected during apoptosis. Exp Cell Res 217:506–516CrossRefPubMed

10.

Yamanaka S, Sunamura M, Furukawa T, Sun L, Lefter LP, Abe T, Yatsuoka T, Fujimura H, Shibuya E, Kotobuki N, Oshimura M, Sakurada A, Sato M, Kondo T, Matsuno S, Horii A (2004) Chromosome 12, frequently deleted in human pancreatic cancer, may encode a tumor suppressor gene that suppresses angiogenesis. Lab Invest 84:1339–1351CrossRefPubMed

11.

Furukawa T, Kanai N, Shiwaku HO, Soga N, Uehara A, Horii A (2006) AURKA is one of the downstream targets of MAPK1/ERK2 in pancreatic cancer. Oncogene 25:4831–4839CrossRefPubMed

12.

Mori Y, Shiwaku H, Fukushige S, Wakatsuki S, Sato M, Nukiwa T, Horii A (1997) Alternative splicing of hMSH2 in normal human tissues. Hum Genet 99:590–595CrossRefPubMed

13.

Xu S, Furukawa T, Kanai N, Sunamura M, Horii A (2005) Abrogation of DUSP6 by hypermethylation in human pancreatic cancer. J Hum Genet 50:159–167CrossRefPubMed

14.

Ogawa K, Shiga K, Saijo S, Ogawa T, Kimura N, Horii A (2006) A novel G106D alteration of the SDHD gene in a pedigree with familial paraganglioma. Am J Med Genet A 140:2441–2446PubMed

15.

Kondo E, Horii A, Fukushige S (1999) The human PMS2L proteins do not interact with hMLH1, a major DNA mismatch repair protein. J Biochem 125:818–825PubMed

16.

Yatsuoka T, Furukawa T, Sunamura M, Matsuno S, Horii A (2004) TU12B1-TY, a novel gene in the region at 12q22–q23.1 frequently deleted in pancreatic cancer, shows reduced expression in pancreatic cancer cells. Oncol Rep 12:1263–1268PubMed

17.

Andrews PA, Howell SB (1990) Cellular pharmacology of cisplatin: perspectives on mechanisms of acquired resistance. Cancer Cells 2:35–43PubMed

18.

Hoskins LK, Whelan RD, Shellard SA, Bedford P, Hill BT (1990) An evaluation of the role of glutathione and its associated enzymes in the expression of differential sensitivities to antitumor agents shown by a range of human tumour cell lines. Biochem Pharmacol 40:1833–1842CrossRef

19.

Hospers GA, Meijer C, de Leij L, Uges DR, Mulder NH, de Vries EG (1990) A study of human small-cell lung carcinoma (hSCLC) cell lines with different sensitivities to detect relevant mechanisms of cisplatin (CDDP) resistance. Int J Cancer 46:138–144CrossRefPubMed

20.

Meijer C, Mulder NH, Timmer-Bosscha H, Sluiter WJ, Meersma GJ, de Vries EG (1992) Relationship of cellular glutathione to the cytotoxicity and resistance of seven platinum compounds. Cancer Res 52:6885–6889PubMed

21.

Robbins KT, Vicario D, Seagren S, Weisman R, Pellitteri P, Kerber C, Orloff L, Los G, Howell SB (1994) A targeted superdose cisplatin chemoradiation protocol for advanced head and neck cancer. Am J Surg 168:419–422CrossRefPubMed

22.

Eckstein N, Servan K, Hildebrandt B, Pölitz A, von Jonquières G, Wolf-Kümmeth S, Napierski I, Hamacher A, Kassack MU, Budczies J, Beier M, Dietel M, Royer-Pokora B, Denkert C, Royer HD (2009) Hyperactivation of the insulin-like growth factor receptor I signaling pathway is an essential event for cisplatin resistance of ovarian cancer cells. Cancer Res 69:2996–3003CrossRefPubMed

23.

Ogawa O, Eccles MR, Szeto J, McNoe LA, Yun K, Maw MA, Smith PJ, Reeve AE (1993) Relaxation of insulin-like growth factor II gene imprinting implicated in Wilms’ tumour. Nature 362:749–751CrossRefPubMed

24.

Sait SN, Nowak NJ, Singh-Kahlon P, Weksberg R, Squire J, Shows TB, Higgins MJ (1994) Localization of Beckwith-Wiedemann and rhabdoid tumor chromosome rearrangements to a defined interval in chromosome band 11p15.5. Genes Chromosomes Cancer 11:97–105CrossRefPubMed

25.

Winkler R, Delacroix L, Bensbaho K, Lambert S, Collette J, Hodzic D (1999) IGF-II in primary human colorectal tumors: Peptide level, activated promoters, parental imprinting and gene rearrangement. Horm Metab Res 31:148–154CrossRefPubMed

26.

Xu W, Fan H, He X, Zhang J, Xie W (2006) LOI of IGF2 is associated with esophageal cancer and linked to methylation status of IGF2 DMR. J Exp Clin Cancer Res 25:543–547PubMed

27.

LeRoith D, Roberts CT Jr (2003) The insulin-like growth factor system and cancer. Cancer Lett 195:127–137PubMed

28.

Anzick SL, Kononen J, Walker RL, Azorsa DO, Tanner MM, Guan XY, Sauter G, Kallioniemi OP, Trent JM (1997) Meltzer PS, AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. Science 277:965–968CrossRefPubMed

29.

Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM (1997) Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569–580CrossRefPubMed

30.

Cartee L, Kucera GL (2000) Protein kinase C modulation and anticancer drug response. Cancer Invest 18:731–739CrossRefPubMed

31.

Beck J, Bohnet B, Brügger D, Bader P, Dietl J, Scheper RJ, Kandolf R, Liu C, Niethammer D, Gekeler V (1998) Multiple gene expression analysis reveals distinct differences between G2 and G3 stage breast cancers, and correlations of PKC eta with MDR1, MRP and LRP gene expression. Br J Cancer 77:87–91PubMed

32.

Beck JF, Bohnet B, Brügger D, Dietl J, Scheper RJ, Bader P, Niethammer D, Gekeler V (1998) Expression analysis of protein kinase C isozymes and multidrug resistance associated genes in ovarian cancer cells. Anticancer Res 18:701–705PubMed

33.

Sonnemann J, Gekeler V, Ahlbrecht K, Brischwein K, Liu C, Bader P, Müller C, Niethammer D, Beck JF (2004) Down-regulation of protein kinase Ceta by antisense oligonucleotides sensitises A549 lung cancer cells to vincristine and paclitaxel. Cancer Lett 209:177–185CrossRefPubMed

Titel: Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma
verfasst von: Takenori Ogawa
Kazumi Ogawa
Kiyoto Shiga
Toru Furukawa
Hiroki Nagase
Sho Hashimoto
Toshimitsu Kobayashi
Akira Horii
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: European Archives of Oto-Rhino-Laryngology / Ausgabe 10/2010
Print ISSN: 0937-4477
Elektronische ISSN: 1434-4726
DOI: https://doi.org/10.1007/s00405-010-1257-4

Neu im Fachgebiet HNO

16.04.2024 | HNO-Chirurgie | Nachrichten

Update HNO

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert – ganz bequem per eMail.

Newsletter bestellen

Springer Medizin

Upregulation of IGF2 is associated with an acquired resistance for cis-diamminedichloroplatinum in human head and neck squamous cell carcinoma

Abstract

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

Piezosurgery® for removal of symptomatic ear osteoma

Steroid treatment of posttraumatic anosmia

Differential β-catenin expression between glottic and supraglottic laryngeal carcinoma

Comparison of conventional B-scan, tissue harmonic imaging, compound imaging and tissue harmonic compound imaging in neck lesion characterisation

Laryngeal findings and acoustic changes in hubble-bubble smokers

Nasopharyngeal carcinoma in a south European population: epidemiological data and clinical aspects in Portugal

Neu im Fachgebiet HNO

HNO-Op. auch mit über 90?

Intrakapsuläre Tonsillektomie gewinnt an Boden

Bilateraler Hörsturz hat eine schlechte Prognose

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Update HNO